ArticleCureus2026
Statin-Induced Hyper-Acute Reversible Liver Failure: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity.Inflammation and regeneration · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins, particularly high-dose atorvastatin, are widely used for cardiovascular prevention but can rarely cause severe hepatotoxicity. We report a case of a male in his seventies who developed hyperacute hepatic failure within 24 hours of initiating atorvastatin 80 mg for secondary stroke prevention. Extensive investigations ruled out alternative causes, and his condition rapidly improved after discontinuation, implicating drug-induced liver injury. This case highlights the unpredictable nature of statin-induced hepatotoxicity, emphasizing the need for vigilance, particularly in elderly patients with comorbidities. Further research is needed to guide safe reintroduction strategies and alternative lipid-lowering options for affected individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.